HEALTH STATE UTILITIES IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TREATED WITH CLADRIBINE TABLETS

被引：0
|
作者：
Wong, S. L. [1 ]
Hohnhorst, P., V [1 ]
Hettle, R. [2 ]
Konings, P. [3 ]
机构：
[1] EMD Serono Inc, Billerica, MA USA
[2] PAREXEL Int, London, England
[3] PAREXEL Int, Stockholm, Sweden
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1961
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND47
引用
收藏
页码：A725 / A725
页数：1
相关论文
共 50 条
  • [21] Low rate of progression independent of relapse in patients with relapsing multiple sclerosis treated with cladribine tablets
    De Stefano, Nicola
    Wiendl, Heinz
    Barkhof, Frederik
    Achiron, Anat
    Derfuss, Tobias
    Chan, Andrew
    Hodgkinson, Suzanne
    Prat, Alexandre
    Leocani, Letizia
    Schmierer, Klaus
    Sellebjerg, Finn
    Vermersch, Patrick
    Petit, Caroline
    Gardner, Lidia
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 350 - 352
  • [22] Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis (vol 25, pg 239, 2011)
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2020, 34 (04) : 447 - 447
  • [23] Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria De Francesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    Applied Health Economics and Health Policy, 2020, 18 : 141 - 141
  • [24] Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells
    Ammoscato, Francesca
    Wafa, Mohammad
    Skonieczna, Justyna
    Bestwick, Jonathan
    Monero, Rosemary
    Andrews, Michael
    De Trane, Stefania
    Holden, David
    Adams, Ashok
    Bianchi, Lucia
    Turner, Ben
    Marta, Monica
    Schmierer, Klaus
    Baker, David
    Giovannoni, Gavin
    Gnanapavan, Sharmilee
    CLINICAL IMMUNOLOGY, 2024, 269
  • [25] The effect of cladribine tablets in patients with relapsing-remitting multiple sclerosis who had evidence of disease activity in CLARITY
    Greenberg, B.
    Rammohan, K.
    Aldridge, J.
    Lebson, L. A.
    Dangond, F.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 916 - 917
  • [26] Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study
    Achiron, Anat
    Warszawer, Yehuda
    Nissan, Yael
    Kerpel, Ariel
    Hoffmann, Chen
    Harari, Gil
    Magalashvili, David
    Tal, Sigal
    MULTIPLE SCLEROSIS JOURNAL, 2025,
  • [27] Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Viglietta, V.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 485 - 485
  • [28] The Effect Of Cladribine Tablets In Patients With Relapsing-remitting Multiple Sclerosis Who Had Evidence Of Disease Activity In CLARITY
    Greenberg, B. M.
    Rammohan, K.
    Aldridge, J.
    Lebson, L. A.
    Dangond, F.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 50 - 50
  • [29] Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
    Moiola, Lucia
    Riva, Agostino
    Nicoletti, Ferdinando
    Uccelli, Antonio
    Salvetti, Marco
    Battistini, Luca
    Furlan, Roberto
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (10) : 1811 - 1815
  • [30] Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
    Ginestal, Ricardo
    Rubio-Terres, Carlos
    Moran, Olga Duran
    Rubio-Rodriguez, Dario
    De Los Santos, Heidi
    Ordonez, Cristina
    Sanchez-Magro, Isabel
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (02)
12345